Paul V. Radspinner

Mr. Radspinner is co-founder, President and Chief Executive Officer of FluGen Inc., a Madison, Wisconsin influenza vaccines company. After completing his MBA at Northwestern University’s Kellogg Graduate School of Management he spent over 15 years in management roles overseeing international pharmaceutical operations, marketing and business development with Eli Lilly and Company. Subsequent to his time at Lilly he managed the pharmaceuticals portfolio including Vitamin D analogs at the Wisconsin Alumni Research Foundation (WARF) for the University of Wisconsin-Madison. Most recently, Mr. Radspinner took on the role of Vice President of Business Development for Deltanoid Pharmaceuticals, Inc. before he started FluGen with Drs. Yoshihiro Kawaoka and Gabriele Neumann in June of 2007. FluGen has raised over $25 million in capital thus far and is slated to initiate phase 2 clinical trials for its universal influenza vaccine candidate in 2018. Mr. Radspinner is a member of the Boards of Directors for Pan Genome Sciences and Co-D Therapeutics Inc.